A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumours

Trial Profile

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Evofosfamide (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Molecular Templates; Threshold Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2017 According to Molecular Templates media release, Threshold Pharmaceuticals merged with Molecular Templates and the combined company is named as Molecular Templates.
    • 01 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top